中国老年保健医学
中國老年保健醫學
중국노년보건의학
CHINESE JOURNAL OF GERIATRIC CARE
2014年
5期
26-27,28
,共3页
翟丽佳%闵凤玲%周玮%高小惠%张丽娜
翟麗佳%閔鳳玲%週瑋%高小惠%張麗娜
적려가%민봉령%주위%고소혜%장려나
急性髓系白血病%老年%重组人粒细胞刺激因子%化疗%骨髓抑制
急性髓繫白血病%老年%重組人粒細胞刺激因子%化療%骨髓抑製
급성수계백혈병%노년%중조인립세포자격인자%화료%골수억제
AML%Aging%Recombinant human granulocyte colony stimulating factor%chemotherapy%myelosuppression
目的:观察CAG(阿克拉霉素+阿糖胞苷+重组人粒细胞刺激因子)/HAG(高三尖杉酯碱+阿糖胞苷+重组人粒细胞刺激因子)预激方案治疗老年初治急性髓系白血病( AML)的临床疗效及不良反应。方法选取2009年6月~2014年5月期间年龄>60岁的AML患者21例,13例采用CAG方案治疗,8例采用HAG方案治疗,同时给予成分输血等支持治疗,缓解后序贯给予DA、MA等方案交替维持治疗,观察临床疗效、不良反应及随访结果。结果21例患者中,完全缓解(CR)14例,部分缓解(PR)2例,无效(NR)5例,总有效率76.19%,主要不良反应为骨髓抑制和感染。随访至2014年8月,死亡19例(90.48%),中位生存时间13个月。结论 CAG/HAG预激方案治疗老年AML有效率高,耐受性好,值得临床推广。
目的:觀察CAG(阿剋拉黴素+阿糖胞苷+重組人粒細胞刺激因子)/HAG(高三尖杉酯堿+阿糖胞苷+重組人粒細胞刺激因子)預激方案治療老年初治急性髓繫白血病( AML)的臨床療效及不良反應。方法選取2009年6月~2014年5月期間年齡>60歲的AML患者21例,13例採用CAG方案治療,8例採用HAG方案治療,同時給予成分輸血等支持治療,緩解後序貫給予DA、MA等方案交替維持治療,觀察臨床療效、不良反應及隨訪結果。結果21例患者中,完全緩解(CR)14例,部分緩解(PR)2例,無效(NR)5例,總有效率76.19%,主要不良反應為骨髓抑製和感染。隨訪至2014年8月,死亡19例(90.48%),中位生存時間13箇月。結論 CAG/HAG預激方案治療老年AML有效率高,耐受性好,值得臨床推廣。
목적:관찰CAG(아극랍매소+아당포감+중조인립세포자격인자)/HAG(고삼첨삼지감+아당포감+중조인립세포자격인자)예격방안치료노년초치급성수계백혈병( AML)적림상료효급불량반응。방법선취2009년6월~2014년5월기간년령>60세적AML환자21례,13례채용CAG방안치료,8례채용HAG방안치료,동시급여성분수혈등지지치료,완해후서관급여DA、MA등방안교체유지치료,관찰림상료효、불량반응급수방결과。결과21례환자중,완전완해(CR)14례,부분완해(PR)2례,무효(NR)5례,총유효솔76.19%,주요불량반응위골수억제화감염。수방지2014년8월,사망19례(90.48%),중위생존시간13개월。결론 CAG/HAG예격방안치료노년AML유효솔고,내수성호,치득림상추엄。
Objectives To observe the therapeutic effects of CAG( Aclacinomycin+cytarabine+Recombinant Human Granulo-cyte Colony-stimulating Factor)/HAG( Homoharringtonine+cytarabine +Recombinant human granulocyte colony stimulating fac-tor) ,as well as drug toxicity related side effects.Methods Between June 2009 and May 2014,21 patients aged over 60 years with acute myeloid leukemia( AML) were recruited and treated with CAG and HAG regime,in which 13 and 8 cases were divided respec-tively.Supportive treatment such as blood component transfusion and sequential therapy of DA or MA were performed as well.Clinical efficacy,side reaction and followed-up outcomes were observed.Results Out of 21 patients,14 achieved complete remission( CR) , 2 partial remission( PR) ,and 5 none remission( NR) ,with a total CR of 76.19%.Main toxic-related side effects included myelosup-pression and infection.By August 2018,19 patients were dead and median survival time was 13 months.Conclusions CAG/HAG regime is highly effective and well tolerant for patients with AML.